Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
2013 · New England Journal of Medicine · 3,421 citations
https://doi.org/10.1056/nejmoa1307684
M
Matthew A. Cavender
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
194
Papers
10.9K
Citations
38
h-index
72
i10-index
Matthew A. Cavender is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Diabetes Treatment and Management & Acute Myocardial Infarction Research & Cardiac Valve Diseases and Treatments. The author has an h-index of 38, co-authored 165 publications.
ORCID: 0000-0002-4466-4760Papers by this author
worksHeart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
2014 · Circulation · 718 citations
https://doi.org/10.1161/circulationaha.114.010389
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
2018 · Journal of the American College of Cardiology · 459 citations
https://doi.org/10.1016/j.jacc.2018.03.009
SGLT-2 Inhibitors and Cardiovascular Risk
2018 · Journal of the American College of Cardiology · 129 citations
https://doi.org/10.1016/j.jacc.2018.01.085
SGLT-2 Inhibitors and Cardiovascular Risk
2018 · Journal of the American College of Cardiology · 129 citations
https://doi.org/10.1016/j.jacc.2018.01.085
Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
2022 · JAMA Network Open · 69 citations
https://doi.org/10.1001/jamanetworkopen.2021.48030
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat